https://www.thepeptidenewsroom.com/glp-1-drugs-linked-to-small-lumbar-bone-density-drop-but-hip-bmd-held-steady/ The Peptide Newsroom en 2026-11-03 GLP-1 Drugs Linked to Small Lumbar Bone Density Drop, But Hip BMD Held Steady https://www.thepeptidenewsroom.com/gelita-says-three-studies-back-collagen-peptides-for-endurance-but-the-numbers-s/ The Peptide Newsroom en 2026-11-03 GELITA Says Three Studies Back Collagen Peptides for Endurance, But the Numbers Stay Behind a Paywall https://www.thepeptidenewsroom.com/fda-flags-compounded-ghrp-2-and-ipamorelin-for-safety-risks-including-reported-d/ The Peptide Newsroom en 2026-11-03 FDA Flags Compounded GHRP-2 and Ipamorelin for Safety Risks, Including Reported Deaths https://www.thepeptidenewsroom.com/datameds-locks-in-supply-deal-for-six-compounded-peptides-but-fda-has-approved-n/ The Peptide Newsroom en 2026-11-03 DataMEDS Locks In Supply Deal for Six Compounded Peptides, But FDA Has Approved None https://www.thepeptidenewsroom.com/california-clinic-pitches-a-hollywood-peptide-stack-but-says-it-is-not-validated/ The Peptide Newsroom en 2026-11-03 California Clinic Pitches a Hollywood Peptide Stack, But Says It Is Not Validated https://www.thepeptidenewsroom.com/us-draft-policy-would-ease-access-to-six-peptides-but-none-are-fda-approved/ The Peptide Newsroom en 2026-11-02 US Draft Policy Would Ease Access to Six Peptides, But None Are FDA-Approved https://www.thepeptidenewsroom.com/midi-health-launches-compounded-sermorelin-but-a-critic-says-the-evidence-lags-t/ The Peptide Newsroom en 2026-11-02 Midi Health Launches Compounded Sermorelin, But a Critic Says the Evidence Lags the Marketing https://www.thepeptidenewsroom.com/kff-health-news-flags-four-misleading-peptide-claims-as-fda-weighs-looser-rules/ The Peptide Newsroom en 2026-11-02 KFF Health News Flags Four Misleading Peptide Claims as FDA Weighs Looser Rules https://www.thepeptidenewsroom.com/combined-sglt2-and-glp-1-therapy-linked-to-fewer-kidney-events-in-large-ckd-reco/ The Peptide Newsroom en 2026-11-02 Combined SGLT2 and GLP-1 Therapy Linked to Fewer Kidney Events in Large CKD Records Analysis